[
  {
    "ts": null,
    "headline": "Revvity trims 2025 profit forecast as China policy changes hit diagnostics demand",
    "summary": "(Reuters) -Revvity on Monday lowered its full-year adjusted profit forecast as it expects demand for diagnostics products in its key market China to be hurt by changes to the country's  reimbursement policy, sending the company's shares down nearly 10%.  The medical equipment maker said that it now expects sales of its diagnostics products to grow in the low single digits this year, compared to its previous forecast of mid-single digit growth.",
    "url": "https://finnhub.io/api/news?id=6eb8bb7e8813bf0fb37d855bf49cfe9698ec77e7888086867c885439ba2bd98c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753704583,
      "headline": "Revvity trims 2025 profit forecast as China policy changes hit diagnostics demand",
      "id": 136108154,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABT",
      "source": "Yahoo",
      "summary": "(Reuters) -Revvity on Monday lowered its full-year adjusted profit forecast as it expects demand for diagnostics products in its key market China to be hurt by changes to the country's  reimbursement policy, sending the company's shares down nearly 10%.  The medical equipment maker said that it now expects sales of its diagnostics products to grow in the low single digits this year, compared to its previous forecast of mid-single digit growth.",
      "url": "https://finnhub.io/api/news?id=6eb8bb7e8813bf0fb37d855bf49cfe9698ec77e7888086867c885439ba2bd98c"
    }
  },
  {
    "ts": null,
    "headline": "Leerink Partners Decreases PT on Abbott Laboratories (ABT) to $136 From $143, Maintains a Hold Rating",
    "summary": "Abbott Laboratories (NYSE:ABT) is one of the top low volatility healthcare stocks to buy now. Analyst Mike Kratky from Leerink Partners reiterated a Hold rating on Abbott Laboratories (NYSE:ABT) on July 21, decreasing the price target to $136.00 from $143.00. The analyst justified the Hold rating with the company’s performance, stating that Abbott Laboratories’ (NYSE:ABT) […]",
    "url": "https://finnhub.io/api/news?id=11a93a2360580e6cafac724243d1789408e55b16487bc4e0fec0546442b2c15e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753682894,
      "headline": "Leerink Partners Decreases PT on Abbott Laboratories (ABT) to $136 From $143, Maintains a Hold Rating",
      "id": 136108155,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABT",
      "source": "Yahoo",
      "summary": "Abbott Laboratories (NYSE:ABT) is one of the top low volatility healthcare stocks to buy now. Analyst Mike Kratky from Leerink Partners reiterated a Hold rating on Abbott Laboratories (NYSE:ABT) on July 21, decreasing the price target to $136.00 from $143.00. The analyst justified the Hold rating with the company’s performance, stating that Abbott Laboratories’ (NYSE:ABT) […]",
      "url": "https://finnhub.io/api/news?id=11a93a2360580e6cafac724243d1789408e55b16487bc4e0fec0546442b2c15e"
    }
  },
  {
    "ts": null,
    "headline": "RBC Capital Sees Strong Growth Potential for Abbott Laboratories (ABT)",
    "summary": "Abbott Laboratories (NYSE:ABT) ranks among the best low volatility stocks to buy according to analysts. RBC Capital maintained its Outperform rating on Abbott Laboratories (NYSE:ABT) on July 15 and raised its price target from $145 to $147. The firm pointed to Abbott’s strong single-digit revenue and double-digit EPS growth potential as examples of its ability […]",
    "url": "https://finnhub.io/api/news?id=0b8c3142ac48d2c73d1c572495878aa785d0ce25091a7ca28366666db1b65d13",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753681322,
      "headline": "RBC Capital Sees Strong Growth Potential for Abbott Laboratories (ABT)",
      "id": 136108156,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABT",
      "source": "Yahoo",
      "summary": "Abbott Laboratories (NYSE:ABT) ranks among the best low volatility stocks to buy according to analysts. RBC Capital maintained its Outperform rating on Abbott Laboratories (NYSE:ABT) on July 15 and raised its price target from $145 to $147. The firm pointed to Abbott’s strong single-digit revenue and double-digit EPS growth potential as examples of its ability […]",
      "url": "https://finnhub.io/api/news?id=0b8c3142ac48d2c73d1c572495878aa785d0ce25091a7ca28366666db1b65d13"
    }
  },
  {
    "ts": null,
    "headline": "Best Dividend Aristocrats For August 2025",
    "summary": "Dividend Aristocrats are outperforming SPY in July but still trail year-to-date. Check out my Promising Aristocrats list here.",
    "url": "https://finnhub.io/api/news?id=830665c984684da2b011aea06a74a0926a66a23d46b32622de0a5dbcf64f981a",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753679992,
      "headline": "Best Dividend Aristocrats For August 2025",
      "id": 136105728,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2189040496/image_2189040496.jpg?io=getty-c-w1536",
      "related": "ABT",
      "source": "SeekingAlpha",
      "summary": "Dividend Aristocrats are outperforming SPY in July but still trail year-to-date. Check out my Promising Aristocrats list here.",
      "url": "https://finnhub.io/api/news?id=830665c984684da2b011aea06a74a0926a66a23d46b32622de0a5dbcf64f981a"
    }
  }
]